Alzheimer’s disease (AD) is the most common form of dementia. It is expected to affect 16 million Americans by 2050. The hallmarks of AD are amyloid plaques and tau neurofibrillary tangles in the brain. Efforts to develop new drugs that directly target amyloid or tau proteins haven’t yielded significant clinical benefits for patients. Another approach to developing AD treatments would be to seek existing drugs that could potentially be repurposed. A team of researchers led by Dr. Feixiong Cheng at the Cleveland Clinic developed a computational method for identifying FDA-approved drugs that might be effective against AD. NIH’s National Institute...
↧
